Angiotensin II  Receptor Antagonists-

Candesartan, Eposartan, Irbestan, Losartan metabolite, Olmesartan, Telmistran, Valsartan

Pot sparing diuretics
Potassium supplements
Salt substitutes

Following myocardial infraction in clinically stable patients with left ventricular failure or systolic dysfunction 

Angiotensin II Receptor Antagonists-

Candesartan, Eposartan, Irbestan, Losartan metabolite, Olmesartan, Telmistran, Valsartan

Angiotensin II Receptor Antagonists-

Candesartan, Eposartan, Irbestan, Losartan metabolite, Olmesatran, Telmistran, Valsartan

Adverse Reactions-

 
VALSARTAN

CNS  -      Dizziness >1% ,Insomnia  >0.2%,  Headache >1% ,Fatigue 2%

                Anxiety/nervousness  > 0.2%

GI  -          Diarrhea >1%  Dyspepsia/heartburn >0.2%  Nausea/voming >1% 

                 Abdomnal pain  2%   

Musculoskeletal-    Arthalgia >1% Pain >0.2%  Muscle cramp >0.2%  Myalgia >0.2%

Respiratory -      Upper Respiratory  tract infn > 1% Cough >1% Sinusitis >1%

                              Pharyngitis >1%    Rhinitis >1%

Miscellaneous -      Viral infection 3%   Edema >1%   Rash > 0.2%                                

Severe hepatic impairment
Cirrhosis,  biliary obstruction,
Pregnancy, lactation

Special precautions-
Mild to moderate hepatic impairment renal impairment
Monitor renal renal function, renal artery stenosis
Cardiac insufficiency
Post - MI patients
Hypotension
Monitor serum K  in elderly and renally impaired if taking K  supplements

Date of Approval      December 2001

Indication-
Following myocardial infraction in clinically stable patients with left ventricular failure
or systolic dysfunction

Dosage-

Initially 20 mg daily twice daily starting as early as 12 hours  post MI
Titrsate gradually over next few weeks to 160mg twice daily according to tolerance
Not recommended for Children

 Angiotensin II Receptor Antagonists-

Candesartan, Eposartan, Irbestan, Losartan metabolite, Olmesartan, Telmistran, Valsartan

Contraindicated during pregnancy and lactation